In the last fifteen years a better understanding of the biological processes promoting tumour growth and progression led to an impressive revolution in metastatic renal cell carcinoma (mRCC) treatment landscape. Angiogenesis plays a critical role in the pathogenesis of RCC. These biological evidences led to targeted therapies interfering with vascular endothelial growth factor and mammalian target of rapamycin pathways. Another big step in the RCC therapeutic landscape was recently made because of the understanding of the interplay between angiogenesis and immune cells. Dual immune checkpoint inhibitors (ICIs) and ICIs plus tyrosine kinase inhibitors (TKI) combinations have been approved considering overall survival benefit compared to targeted therapies as first line treatment. We summarize the activity and the biological rationale of ICIs combinations as mRCC first line therapy. Additionally, we review the clinical and biological criteria useful to guide clinicians in the choice of treatment sequencing focusing on ICIs combinations resistance mechanisms.

Therapeutic sequencing in advanced renal cell carcinoma: how to choose considering clinical and biological factors

Delcuratolo, Marco Donatello;Tucci, Marcello;Turco, Fabio;Di Stefano, Rosario Francesco;Ungaro, Antonio;Audisio, Marco;Samuelly, Alessandro;Audisio, Alessandro;Di Maio, Massimo;Scagliotti, Giorgio Vittorio;Buttigliero, Consuelo
2023-01-01

Abstract

In the last fifteen years a better understanding of the biological processes promoting tumour growth and progression led to an impressive revolution in metastatic renal cell carcinoma (mRCC) treatment landscape. Angiogenesis plays a critical role in the pathogenesis of RCC. These biological evidences led to targeted therapies interfering with vascular endothelial growth factor and mammalian target of rapamycin pathways. Another big step in the RCC therapeutic landscape was recently made because of the understanding of the interplay between angiogenesis and immune cells. Dual immune checkpoint inhibitors (ICIs) and ICIs plus tyrosine kinase inhibitors (TKI) combinations have been approved considering overall survival benefit compared to targeted therapies as first line treatment. We summarize the activity and the biological rationale of ICIs combinations as mRCC first line therapy. Additionally, we review the clinical and biological criteria useful to guide clinicians in the choice of treatment sequencing focusing on ICIs combinations resistance mechanisms.
2023
Jan
181
1
13
combination therapy; immunotherapy; metastatic renal cell carcinoma; tyrosine kinase inhibitor
Delcuratolo, Marco Donatello; Tucci, Marcello; Turco, Fabio; Di Stefano, Rosario Francesco; Ungaro, Antonio; Audisio, Marco; Samuelly, Alessandro; Brusa, Federica; Audisio, Alessandro; Di Maio, Massimo; Scagliotti, Giorgio Vittorio; Buttigliero, Consuelo
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S1040842822003055-main.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 1.77 MB
Formato Adobe PDF
1.77 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1882402
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 3
social impact